我武生物：终止烟曲霉点刺液研发项目，或影响2025年净利润334万元

Core Viewpoint - The company has decided to terminate the research and development project for the Aspergillus niger puncture solution due to the assessment of risks and project progress, focusing on more advantageous projects in its pipeline [1][2]. Group 1: Project Termination - The management evaluated the project and decided to stop further clinical trials for the Aspergillus niger puncture solution [1][2]. - The decision was influenced by the occurrence of delayed reactions during Phase I clinical trials, specifically the appearance of blisters at the puncture site, which occurred in 9.1% of cases [1][2]. - The company cited difficulties in identifying and removing components in the Aspergillus niger solution that could cause delayed reactions, leading to the termination of the project [2]. Group 2: Financial Impact - As of the announcement date, the total development expenditure for the Aspergillus niger puncture solution project was 4.77 million yuan, and the company will fully recognize an impairment provision [2]. - The expected reduction in net profit attributable to the parent company for the year 2025 is estimated to be 3.34 million yuan [2].